FDA fast tracks DNA therapy for MS-related bladder issue
EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.| Multiple Sclerosis News Today
EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.| Multiple Sclerosis News Today
“I know where every bathroom is at the mall, and my wife rolls her eyes every time I have to visit one when we just arrived – even after I went before leaving the house! What can I expect? Most old guys are in the same boat!” If you opened this article, you probably relate […]| Better Health While Aging
